Additional mortality benefits were found at a moderate-to-high versus low step cadence<\/p>\n<\/h3>\n
By Lori Solomon HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, Dec. 6, 2023 (HealthDay News) — Cardiovascular disease (CVD) benefits can be seen from as few as about 2,600 steps per day, according to a review recently published in the\u00a0Journal of the American College of Cardiology<\/em>.<\/p>\n Niels A. Stens, from Radboud University Medical Center in Nijmegen, Netherlands, and colleagues conducted a meta-analysis to quantify dose-response associations between objectively measured step count metrics in the general population. The analysis included 111,309 individuals from 12 studies.<\/p>\n The researchers found significant risk reductions with 2,517 steps\/day for all-cause mortality (adjusted hazard ratio [aHR], 0.92) and 2,735 steps\/day for incident CVD (aHR, 0.89) versus 2,000 steps\/day (reference). There was a nonlinear risk reduction seen for additional steps and risk for all-cause mortality and incident CVD with an optimal dose at 8,763 (aHR, 0.40) and 7,126 steps\/day (aHR, 0.49), respectively. There was an independent relationship observed for increments from a low to an intermediate or a high cadence and risk reductions of all-cause mortality. There was no dose-response association seen with sex. After stratification for assessment device and wear location, the investigators found pronounced risk reductions for hip-worn accelerometers versus pedometers and wrist-worn accelerometers.<\/p>\n “These findings can extend contemporary physical activity prescriptions given the easy-to-understand concept of step count,” the authors write.<\/p>\n Abstract\/Full Text\u00a0(subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n